Skip to main content
. 2018 Oct 1;9(20):3787–3796. doi: 10.7150/jca.26275

Fig 5.

Fig 5

Pharmaceutical inhibition of EZH2 selectively inhibited ccRCC with BAP1 mutation. EZH2 inhibitor EPZ011989 significantly and selectively inhibited (A) cell invasion, (B) migration, (C) colony formation, and (D) animal weight, and (E) tumor growth of ccRCC with BAP1 mutation or KD (*P<0.05, **P < 0.01).